Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.
Urology. 2020 Apr;138:69-76. doi: 10.1016/j.urology.2019.12.032. Epub 2020 Jan 28.
To compare a simultaneous vs sequential approach to residual post chemotherapy mass resections in metastatic testis cancer.
A retrospective review was performed of patients who underwent retroperitoneal and thoracic/cervical resection of post chemotherapy residual masses between 2002 and 2018. Group 1: "Simultaneous" (Combined Retroperitoneal and Thoracic/Cervical resections on the same date); Group 2: "Sequential" (Retroperitoneal and Thoracic/Cervical resections at separate dates).
During the study period, 35 simultaneous and 17 sequential resections were performed. The median age at surgery was 28 years (Range 16-61). The median follow-up from last surgical procedure was 62.7 months (Range 0.4-194). Histology revealed teratoma in 38 (73.1%) patients, necrosis in 8 (15.4%) and viable tumor in 6 (11.5%). Discordant pathology findings between thoracic/cervical and abdominal resections were noted in 16 (30.8%) patients. No differences were observed between the simultaneous vs sequential groups in median operating time (585 minutes vs 545 minutes, P = .64), blood loss (1300 vs 1300 mls, P = .42), or length of stay (9 vs 11 days, P = .14). There was no difference between the 5-year (65.7% vs 68.6%) relapse-free survival between the 2 groups (P = .84) or the 5-year (88.6% vs 100%) overall and disease-specific survival (P = .25).
Simultaneous resection of retroperitoneal and thoracic/cervical post chemotherapy metastases is a feasible in some patients. It requires multidisciplinary collaboration and a longer primary procedure.
比较转移性睾丸生殖细胞瘤化疗后残留肿块的同期与序贯切除方法。
对 2002 年至 2018 年间接受化疗后残留肿块腹膜后和胸/颈切除术的患者进行回顾性研究。第 1 组:“同期”(同一天进行腹膜后和胸/颈联合切除术);第 2 组:“序贯”(在不同日期进行腹膜后和胸/颈切除术)。
研究期间,共进行了 35 例同期和 17 例序贯切除术。手术时的中位年龄为 28 岁(范围 16-61 岁)。末次手术随访中位数为 62.7 个月(范围 0.4-194 个月)。组织学显示 38 例(73.1%)患者为畸胎瘤,8 例(15.4%)为坏死组织,6 例(11.5%)为存活肿瘤。16 例(30.8%)患者的胸/颈和腹部切除标本的病理结果不一致。同期组与序贯组的中位手术时间(585 分钟比 545 分钟,P=0.64)、失血量(1300 毫升比 1300 毫升,P=0.42)或住院时间(9 天比 11 天,P=0.14)无差异。两组 5 年无复发生存率(65.7%比 68.6%,P=0.84)或 5 年总生存率(88.6%比 100%,P=0.25)和疾病特异性生存率(88.6%比 100%,P=0.25)无差异。
在某些患者中,同期切除化疗后腹膜后和胸/颈转移灶是可行的。它需要多学科合作和更长的主要手术过程。